Delores Malaspina, M.D., M.S., MSPH, Director of the Psychosis Program at the Icahn School of Medicine at Mount Sinai, will present this work in an upcoming BBRF-hosted webinar, "The Gut-Brain Axis ...

What started out as a medication for diabetes and weight loss is offering something quite unexpected for many women. Experts ...

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

The Portsmouth Redevelopment and Housing Authority has opened Lexington Reserve, a new senior living community. Located on ...

Eating disorders and OCD can look strikingly similar on the surface. Understanding what drives the behavior is essential for ...

When people picture someone with an eating disorder, many think of a thin teenage girl with anorexia nervosa. This stereotype ...

No matter how educated you are, how many degrees or skills you have, how many weights you can lift, how many dishes you can ...

CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring ...

CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading ...

To make cancer care smoother and more effective, the Alliance for Clinical Trials in Oncology has introduced a new clinical ...

As Novo Nordisk launches first FDA-approved oral weight loss medication, independent examination evaluates Ro's ...

GLP-1 agonists and dual agonists can cause hypoglycemia, nausea, and more. Here's how to lessen the side effects.